Skip to main content
. 2022 Nov 30;12:1021632. doi: 10.3389/fonc.2022.1021632

Figure 2.

Figure 2

LCL161 synergistically enhances the drug efficacy of GEM/CIS. (A, B) Triplet LCL161 + GEM/CIS therapy effectively inhibits multidrug-resistant cells. Percent cell survival of TFK1, TFK1R, KKU213C, and KKU213CR cells treated with LCL161 at 2.5 µM, or GEM/CIS at 0.01/0.1 µM, or LCL161 + GEM/CIS, and of (C, D) TFK1, TFK1R, KKU213C, and KKU213CR cells treated with Birinapant at 2.5 µM, GEM/CIS at 0.01/0.1 µM, or Birinapant + GEM/CIS for 5 days. The bars represent the averages of 4 replicates ± SD. Analysis for statistical significance was performed using Student’s t-test, and the p-values are shown above the bars in all 4 images. (E) Dose-response curves for TFK1 and TFK1R cells treated with LCL161, GEM/CIS, or LCL161 + GEM/CIS. (F) Dose-response curves for TFK1 and TFK1R cells treated with Birinapant, GEM/CIS, or Birinapant + GEM/CIS. (G) Dose-response curves for KKU213C and KKU213CR cells treated with LCL161, GEM/CIS, or LCL161 + GEM/CIS. (H) Dose-response curves for KKU213C and KKU213CR cells treated with Birinapant, GEM/CIS, or Birinapant + GEM/CIS. (I–L) The combination indexes (CIs) of LCL161 + GEM/CIS in TFK1, TFK1R, KKU213C, and KKU213CR cells. The colors indicate the proportion of respondents. A CI < 1, CI = 1, and CI > 1 indicate synergism, additive effect, and antagonism, respectively.